Form D · Other Health Care

AVAXIA BIOLOGICS, Inc

Lexington, MA · CIK 0001534899

Offering snapshot reported Jul 21, 2015 · SEC filing

Reported sold
$1.01M
Offering amount: $5M
Investors reported
44
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 6, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 21, 2015Initial$1,005,777No comparison44SEC filing
May 6, 2014Initial$3,096,371No comparison95SEC filing
Dec 20, 2013Initial$2,872,388No comparison102SEC filing
Jun 7, 2013Amendment$11,457,321$7,431,996vs Dec 27, 2012164SEC filing
Dec 27, 2012Initial$4,025,325No comparison120SEC filing
Jan 6, 2012Amendment$3,443,378$1,162,039vs Nov 18, 201194SEC filing
Nov 18, 2011Initial$2,281,339No comparison48SEC filing

Offering details

Securities
Equity, Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-244159

Source: Form D, filed Jul 21, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Eileen F. Bostwick Executive
David C. Dlesk Executive
David Donabedian Director
John Edwards Director
Jonathan Fleming Director
Barbara S. Fox Director, Executive
Nada Jain Director
Henry Kay Director
Christopher Kiritsy Director
Robert Manning Director
David Poorvin Director

Issuer details

Industry: Other Health Care (See others in industry)

Address:
128 Spring St., Ste 620
Lexington, MA, 02421